Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | YAP1 | P46937 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977266 | 1.00 | KDM4E (0.61) | KDM4EPKMTGFBR1GPR119STS | |
| SCHEMBL3541890 | 0.82 | ALDH1A1 (0.50) | KDM4EPKMKDM1ATP53LMNA | |
| SCHEMBL13316325 | 0.82 | ALDH1A1 (0.50) | KDM4EPKMKDM1ATP53LMNA | |
| SCHEMBL3539984 | 0.82 | ALDH1A1 (0.50) | KDM4EPKMKDM1ATP53LMNA | |
| SCHEMBL3539982 | 0.82 | ALDH1A1 (0.50) | KDM4EPKMKDM1ATP53LMNA | |
| SCHEMBL3595874 | 0.82 | ALDH1A1 (0.50) | KDM4EPKMKDM1ATP53LMNA | |
| SCHEMBL18172576 | 0.81 | KDM1A (0.60) | KDM4EPKMTGFBR1GPR119STS | |
| SCHEMBL18172579 | 0.81 | KDM1A (0.60) | KDM4EPKMTGFBR1GPR119STS | |
| SCHEMBL14419140 | 0.79 | KDM4E (0.73) | KDM4EPKMGPR119 | |
| SCHEMBL7985552 | 0.79 | KDM4E (0.69) | KDM4EPKMTGFBR1GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517991-B2 | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1814550-A2 | N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006044362-A2 | N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079556-A1 | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079556-A1 | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | CNR1, CNR2, NPY1R | KDM4E 2122/4885PKM 3378/4885TGFBR1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.